Uceris (Ulcerative Colitis) – Forecast and Market Analysis to 2022
Uceris (Ulcerative Colitis) – Forecast and Market Analysis to 2022
Summary
During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson’s (J&J’s) Simponi and Takeda’s Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.
Uceris is a synthetic steroid of the glucocorticosteroid family that is indicated for mild-to-moderate UC. It is formulated as a slow-release foam that is administered rectally. Uceris binds to glucocorticoid receptors and causes suppression of endogenous cortisol concentrations and impairment of the hypothalamus-pituitary-adrenal (HPA) axis function. Budesonide has mainly anti-inflammatory activity, and due to an extended first-pass effect, Uceris has less systemic absorption than other corticosteroids.
Scope
– Overview of Ulcerative Colitis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
– Detailed information on Uceris including product description, safety and efficacy profiles as well as a SWOT analysis.
– Sales forecast for Uceris for the top seven countries from 2012 to 2022.
– Sales information covered for the US, France, Germany, Italy, Spain, the UK and Canada.
Reasons to buy
– Understand and capitalize by identifying products that are most likely to ensure a robust return
– Stay ahead of the competition by understanding the changing competitive landscape for Ulcerative Colitis
– Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
– Make more informed business decisions from insightful and in-depth analysis of Uceris performance
– Obtain sales forecast for Uceris from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Canada)
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 13
3.2 Symptoms 15
3.2.1 Quality of Life 15
4 Disease Management 17
4.1 Diagnosis and Treatment Overview 17
4.1.1 Diagnosis 17
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 20
4.1.3 Clinical Practice 22
5 Competitive Assessment 26
5.1 Overview 26
5.2 Strategic Competitor Assessment 27
6 Uceris (budesonide) 29
6.1 Overview 29
6.2 Efficacy 29
6.3 Safety 30
6.4 SWOT Analysis 30
6.5 Forecast 31
7 Appendix 33
7.1 Bibliography 33
7.2 Abbreviations 35
7.3 Methodology 38
7.4 Forecasting Methodology 38
7.4.1 Diagnosed UC Patients 38
7.4.2 Percent Drug-Treated Patients 39
7.4.3 General Pricing Assumptions 39
7.4.4 Generic Erosion 40
7.5 Physicians and Specialists Included in This Study 40
7.6 Primary Research - Prescriber Survey 42
7.7 About the Authors 43
7.7.1 Author 43
7.7.2 Global Head of Healthcare 44
7.8 About GlobalData 45
7.9 Disclaimer 45
1.1 List of Tables
Table 1: Genetic Factors That Confer a Predisposition to UC 13
Table 2: Typical Symptoms of UC 15
Table 3: Truelove and Witts UC Severity Index 19
Table 4: UCDAI 20
Table 5: Treatment Guidelines for UC Used in the 10MM 21
Table 6: Most Commonly Prescribed Drugs for UC by Class in the 10MM, 2013 22
Table 7: Leading Treatments for UC, 2014 28
Table 8: Product Profile - Uceris 29
Table 9: Uceris SWOT Analysis, 2014 31
Table 10: Global Sales Forecasts ($m) for Uceris, 2012-2022 32
Table 11: Physicians Surveyed, By Country 42
1.2 List of Figures
Figure 1: Cellular Mechanisms Involved in the Pathogenesis of UC 14
Figure 2: UC Disease Management Flowchart 25